Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

33.55 -0.29 (-0.86%)
Streaming Delayed Price Updated: 11:39 AM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Eli Lilly has seen revenue and earnings soar in recent years. 
Via The Motley Fool
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗
Via Stocktwits
News headline image
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗
Is this the best way to cash in on the weight-loss gold rush? 
Via The Motley Fool
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Why Viking Therapeutics Stock Is Up More Than 9% Today ↗
A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow. 
Via The Motley Fool
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing... 
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated... 
Via MarketMinute
Topics Earnings
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Viking stock has plenty of room to run. 
Via The Motley Fool
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Really Going to $125? ↗
Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly. 
Via The Motley Fool
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Viking should have plenty of news to share with investors this year. 
Via The Motley Fool
News headline image
The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge
The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗
The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts. 
Via Stocktwits
News headline image
Viking Therapeutics Stock Soars: What&#39;s Driving The Momentum? ↗
Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release. 
Via Benzinga
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Viking (VKTX) Q4 2025 Earnings Call Transcript ↗
Viking (VKTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗
Via Stocktwits
Topics Government Stocks
News headline image
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity. 
Via Stocktwits
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
This stock has been known to soar after good news. 
Via The Motley Fool
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Could these two companies be biotech giants in the making? 
Via The Motley Fool
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
The stock has climbed in the triple digits over the past three years. 
Via The Motley Fool
News headline image
3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗
The most recent gold rush in weight loss drugs isn't done just yet. 
Via The Motley Fool
Topics Economy
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Smartest Growth Stock to Buy With $30 Right Now ↗
This pre-revenue biopharmaceutical stock is a home run swing worth taking. 
Via The Motley Fool
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
They could perhaps see sustained runs beyond this year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.